呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

2018年 ERS：Dupilumab显著改善中重度哮喘和合并症患者的症状

2018-09-19 MedSci MedSci原创

中重度哮喘DupilumabERS
关注

在2018年欧洲呼吸学会国际大会（ERS）上发表的III期QUEST试验的结果显示，Dupilumab为患有慢性鼻窦炎或鼻息肉病（CRS / NP）的中度至重度哮喘患者提供更好的症状控制，显著改善了与健康相关的生活质量（HRQoL）。

在2018年欧洲呼吸学会国际大会（ERS）上发表的III期QUEST试验的结果显示，Dupilumab为患有慢性鼻窦炎或鼻息肉病（CRS / NP）的中度至重度哮喘患者提供更好的症状控制，显著改善了与健康相关的生活质量（HRQoL）。

在本研究中，威斯康星大学麦迪逊分校的William W. Busse博士于9月16日介绍了这项研究，他和同事随机分配了1,902名患者（2：2：1：1）接受皮下注射dupilumab 300 / 200 mg或安慰剂2毫升 / 1.14 毫升，每2周注射一次，持续52周。终点是12周，24周和52周中鼻结果测试（SNOT-22）评分相比于基线的变化。结果显示，与安慰剂相比，dupilumab在第12，24和52周时改善了中鼻结果测试（SNOT-22）评分。第12周时评分得到改善，并在第24周和第52周时得以维持。研究人员随后分析了382例合并有CRS / NP的患者，并对HRQoL进行了评估。结果显示，使用dupilumab 200和300 mg的患者评分从基线到第12周的最小二乘平均差异（标准误差）分别为-13.81和-15.77，这一数据在安慰剂2毫升 / 1.14 毫升的患者中分别为-5.68和-9.75，因此Dupilumab显著改善了改善中重度哮喘和合并症患者症状。


原始出处：

http://www.firstwordpharma.com/node/1591931#axzz5RYfGAMOs

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2019-02-05 lvliquan

    #合并症#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2019-04-06 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2019-03-26 ymljack

    #中重度哮喘#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-10-12 anminleiryan

    #ERS#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2019-07-12 小几洁

    #重度哮喘#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-09-21 zhyy88

    #Dupilumab#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-09-20 txqjm

    谢谢了，学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1825856, encodeId=e9b31825856c7, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Feb 05 02:48:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912035, encodeId=304b191203535, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 06 17:48:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940241, encodeId=b91819402418e, content=<a href='/topic/show?id=85092258234' target=_blank style='color:#2F92EE;'>#中重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22582, encryptionId=85092258234, topicName=中重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Mar 26 08:48:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878283, encodeId=dd2318e828392, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 12 01:48:00 CST 2018, time=2018-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663683, encodeId=1654166368375, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Fri Jul 12 06:48:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282902, encodeId=d5cc128290272, content=<a href='/topic/show?id=5a67633069' target=_blank style='color:#2F92EE;'>#Dupilumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6330, encryptionId=5a67633069, topicName=Dupilumab)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Fri Sep 21 14:48:00 CST 2018, time=2018-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345761, encodeId=976b345e61f4, content=谢谢了，学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Sep 20 06:11:51 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345758, encodeId=c918345e58e1, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=47a52446203, createdName=123e5f57m18暂无昵称, createdTime=Thu Sep 20 00:37:08 CST 2018, time=2018-09-20, status=1, ipAttribution=)]
    2018-09-20 123e5f57m18暂无昵称

    学习了

    0